GomerBlog

Haldol Blowdart Halted in Phase 3 Clinical Trial Due to ‘Safety Concerns’

MORRISTOWN, NJ – Recognizing the mounting need for new and creative ways to quickly administer haloperidol (a typical antipsychotic drug) to that “difficult” patient, Big Pharma Pharmaceuticals (BPP) outside Morristown, NJ had planned to release “HalBlow” in the 2nd quarter of 2016.

“Everyone out of the way!!  Incoming HalBlow!”

A single haloperidol dose of 10mg IM comes pre-loaded in a one-time use cylinder that the treating physician, PA, NP, CRNA, RN, CNA, RT, or dentist simply has to take aim and fire with a decent puff of air.  “The blowdart’s auto-injector takes care of the rest,” stated lead researcher Dr. Mick Dundee, PhD.  “The clinician can remain safely hidden behind an overturned commode or medication cart while the drug takes effect and the patient drifts off to sleep.”

Much to shareholders’ delight, the new drug delivery system sailed through the animal testing phase where, after a brief safety tutorial, clinicians found they could easily drop a fully grown charging male baboon from 10 feet, or approximately the distance from the hallway to a patient’s bed, with a quick blast of air through the end of the blowgun.

Dundee explained, “Ideally the ‘problem’ patient is struck with the dart in an area of exposed neck or perhaps the buttock.  But, quite honestly, the drug delivery system is designed to be able to penetrate clothing and even a lunch tray if the patient has opted to use one as a shield.”

Unfortunately when the “blowdart” format of the drug was compared head-to-head to more standard administration techniques such as direct IV or IM injection by a nursing professional, some safety concerns were raised.  “Look, no drug delivery system is perfect, there is a learning curve with this product,” Dundee stated, alluding to a recent incident at a trial site where 3 orderlies and two cafeteria workers were incidentally sedated by “Halblow” missiles before the individual in question was eventually subdued.